We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -7.00 | -0.51% | 1,356.50 | 5,013,886 | 16:29:58 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1,356.00 | 1,356.50 | 1,370.00 | 1,353.00 | 1,365.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.41 | 56.52B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:26 | O | 8 | 1,357.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 20/1/2025 | 08:40 | ALNC |  GSK gets EU nod for expanded use of Jemperli in endometrial cancer |
| 20/1/2025 | 07:00 | UK RNS | GSK PLC Jemperli expanded approval in the EU |
| 16/1/2025 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 15/1/2025 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 14/1/2025 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 13/1/2025 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 13/1/2025 | 09:08 | ALNC | GSK to buy precision therapeutics firm IDRx for up to USD1.15 billion |
| 13/1/2025 | 07:00 | UK RNS | GSK PLC GSK enters agreement to acquire IDRx, Inc. |
| 10/1/2025 | 08:58 | ALNC | GSK awaits FDA review of new shingles vaccine presentation |
| 10/1/2025 | 07:00 | UK RNS | GSK PLC Shingrix fully liquid accepted for US FDA review |
Gsk (GSK) Share Charts1 Year Gsk Chart |
|
1 Month Gsk Chart |
Intraday Gsk Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 23/1/2025 | 14:08 | Glaxosmithkline - The recovery | 33,936 |
| 15/11/2024 | 10:28 | GLAXOSMITHKLINE WITH CHARTS & NEWS | 191 |
| 15/11/2024 | 10:22 | GSK | 73 |
| 10/10/2024 | 05:29 | GlazoSmithKline - News & Information | 148 |
| 17/4/2023 | 18:25 | Gsk zantac | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-01-24 17:21:15 | 1,357.50 | 8 | 108.60 | O |
| 2025-01-24 17:21:15 | 1,357.50 | 32 | 434.40 | O |
| 2025-01-24 17:18:57 | 1,356.50 | 1 | 13.57 | O |
| 2025-01-24 17:18:57 | 1,357.50 | 1 | 13.58 | O |
| 2025-01-24 17:12:48 | 1,356.00 | 29 | 393.24 | O |
| Top Posts |
|---|
Posted at 25/1/2025 08:20 by Gsk Daily Update Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,363.50p.Gsk currently has 4,145,132,579 shares in issue. The market capitalisation of Gsk is £56,228,723,434. Gsk has a price to earnings ratio (PE ratio) of 11.41. This morning GSK shares opened at 1,365p |
Posted at 22/1/2025 09:16 by tradermichael Yes, on the price-to-earnings ratio, it trades at just 21.6 – bottom of its peer group, which averages 29.1. This comprises Merck KGaA at 22.8, both Zoetis and AstraZeneca at 31, and CSL at 31.4. So, GSK looks very undervalued on that basis.The same is true on the key price-to-book and price-to-sales ratios. On the former, GSK currently trades at 3.9 against a competitor average of 6.6. And on the latter, it is presently at 1.7 compared to a 5.2 average for its peers. The second part of this pricing assessment examines where GSK shares should be, based on future cash flow forecasts. This discounted cash flow analysis shows the stock is 70% undervalued at its current £13.58 price. Therefore, the fair value of the stock is technically £45.27! Market unpredictability may move it lower or higher than this. But it underlines that the stock is absolutely packed with value right now. |
Posted at 08/1/2025 10:41 by geckotheglorious Not going to help sentiment sadly.."GSK, Pfizer RSV shots to get warning of rare neurological disorder" The U.S. FDA is ordering that respiratory syncytial virus (RSV) vaccines marketed by GSK (NYSE:GSK) and Pfizer (NYSE:PFE) contain a warning on labeling of the risk of developing the rare neurological disorder Guillain-Barré syndrome ("GBS"). The FDA Safety Communication impacts GSK's Arexvy and Pfizer's Abrysvo. The agency said&nbs Analyses of all GBS cases based on claims data suggest an increased risk of the disease during the 42 days following vaccination, with an estimated nine excess cases of GBS per million doses of Abrysvo, and seven excess cases per million doses of Arexvy, according to the FDA. With GBS, an individual's immune system wrongly attacks part of their peripheral nervous system, which carries signals from the brain and spinal cord to the rest of the body. |
Posted at 17/12/2024 13:58 by tradermichael GSK plc (LSE/NYSE: GSK), a global biopharmaceutical company, announced today that the European Medicines Agency (EMA) has granted its investigational drug, GSK'227, the Priority Medicines (PRIME) designation for the treatment of relapsed extensive-stage small-cell lung cancer (ES-SCLC). This regulatory acknowledgment is based on early clinical data suggesting potential therapeutic benefits in a disease marked by limited treatment options and poor patient outcomes.The PRIME designation is designed to expedite the development and review of drugs targeting unmet medical needs. GSK'227, an antibody-drug conjugate (ADC) targeting B7-H3, has shown promise in preliminary trials. It is the second major regulatory milestone for GSK'227, following the Breakthrough Therapy Designation it received from the US Food and Drug Administration in August 2024. Senior Vice President of Global Head Oncology at GSK, Hesham Abdullah, remarked on the significance of this development, noting the potential of GSK'227 to improve treatment for ES-SCLC and other tumor types with limited therapeutic options. The PRIME designation was supported by data from the ARTEMIS-001 study, an ongoing phase I trial conducted by Hansoh Pharma, which assessed the drug's safety and efficacy in over 200 patients with various advanced solid tumors. Lung cancer remains one of the leading causes of cancer-related deaths globally. In Europe alone, lung cancer accounted for an estimated 484,554 new cases and 375,784 deaths in 2022. ES-SCLC, a particularly aggressive form of lung cancer, often presents with widespread disease at diagnosis and has a high rate of relapse after initial treatment. |
Posted at 12/12/2024 16:43 by geckotheglorious Two stocks to buy in a cheap sectorThere are a couple of companies in this sector that have been oversold and are being tipped to do well. Another remains one to avoid, writes Graeme Evans. AstraZeneca and Novo Nordisk are the leading picks and GSK is still one to avoid after a City bank revealed its 2025 forecasts for an “inexpensive&r Bank of America said the industry’s fundamentals remain strong, with the European majors set to deliver another year of market-beating earnings growth in the region of 14%. However, this has been offset by stock-specific issues and the potential for uncertainty over healthcare policy in the sector’s single largest and most profitable market of the US. As a result, European pharma trades on 12 times forecast 2026 earnings. That’s a slim 3% premium to the wider market, whereas the long-term average is 12%. The bank believes the weakness since September has been overdone and that valuations are too focused on risks rather than growth and the potential of pipelines. Its target multiple of 16 times implies a 30% total return potential if overhangs are removed. Despite its multiple of seven times 2026 earnings making GSK GSK 0.34% one of the lowest-rated stocks in the sector, the bank continues to have an Underperform recommendation. This reflects headwinds for vaccines Arexvy and Shingrix, as well as GSK having the worst post-2026 growth outlook in the sector due to the loss of exclusivity on key products. The shares are down 9% this year, despite the company recently ending two years of uncertainty by setting aside $2.2 billion to settle 93% of Zantac litigation claims. Third-quarter results in late October showed vaccine sales fell 15%, impacted by a tough comparative and the prioritisation of Covid vaccinations in the United States. Shingles product Shingrix dropped 7% as lower demand in the US more than offset stronger international uptake. And the respiratory syncytial virus vaccine Arexvy also missed City targets by some distance, with a 72% decline to £188 million. The pressure on GSK shares and other European pharma stocks continued at the end of November after president-elect Donald Trump nominated vaccine-sceptic Robert F. Kennedy Jr as health secretary. While this brings the prospect of four years of uncertainty over healthcare policy, Bank of America believes this is already reflected in the sector's discounted P/E multiple. |
Posted at 04/12/2024 10:32 by anhar If I were investing for capital growth then GSK which I've held for a very long time would be an utter crock. In fact the only reason my combined GSK/HLN holding is showing a small profit over my original cost of old GSK all those years ago is because HLN has boomed, up 51% on its allocated cost in the demerger, whilst new GSK is making a loss.But I'm not a growth player, I'm an income investor and usually hold long term so don't trade much. However the income situation is not too attractive either because the total income from GSK+HLN is well below the 80p old GSK was paying pre-demerger. And even that 80p had been frozen for several years. Not bad enough to dump but disappointing after decades. Still, that's the point of a diversified port where inevitably some sectors will do better than others but the essential trade-off is that risks are spread. |
Posted at 30/10/2024 18:53 by pj84 Positive update from HL"GSK: full-year guidance confirmed despite weak Q3 vaccine sales GSK beat Q3 earnings estimates due to growth in its specialty medicines. Written by Derren Nathan Head of Equity Research Oct 30, 2024 No recommendation Underlying operating profit rose by 5% to £2.8bn, driven by revenue growth and effective cost management. Underlying earnings per share also grew 5% to 49.7p, ahead of market forecasts of 43.5p. Free cash flow fell 20% to £1.3bn largely driven by the acquisition of rights to certain vaccine technologies. Net debt has fallen from £15.0bn to £12.8bn since the start of the year. GSK recognised a £1.8bn charge in relation to the Zantac settlement, with the ‘vast majority’ of cases now settled. With all full-year guidance unchanged, pointing to underlying operating profit growth in the 11-13% range. The third-quarter dividend rose from 14p to 15p. The shares were down 3.6% in early trading. Our view GSK’s on track to meet upgraded estimates despite ongoing weakness in it’s vaccine portfolio. Two key products, Arexvy and Shingrix were coming up against headwinds in the important US market. But both products still have the potential to reach new patient populations. The financial progress is underpinned by excellence in research & development that’s seen 11 positive late stage clinical updates so far this year, and is expected to yield five major product approvals next year. However, there can be no guarantee of continued success. Falling sales of COVID-19 medicines have held back growth but now that they are no longer material, comparatives are becoming less demanding. Beyond vaccines, the group also has a strong presence in HIV treatments which make up about 20% of total revenues. Its newer HIV treatments are a key part of GSK's future, as generic competitors eat away at pricing power for some of the group's legacy treatments. But the group focus for HIV is shifting to long-acting innovation therapies. And it’s these that have helped capture additional market share and drive double-digit growth for the category in the first half. Apretude is another important product to watch in the space. It’s the only approved medicine in its class and real-world studies have shown it to be 99% effective at preventing HIV infections. Cancer treatment, although relatively small in terms of current sales, is growing rapidly. Recent approvals and launches in new markets mean there are strong growth drivers for the existing portfolio. The development pipeline looks promising. Net debt has been coming down and currently sits at under 1.3x forecast cash profits, which we don't see as a major concern. The strong financial position and improving cash generation helps support a prospective dividend yield of 4.4%, but remember, no future payouts to shareholders can be assured. GSK's valuation is below the long-term average, and significantly less demanding than many of its peers. One reason it’s been held back was uncertainty over the financial impact of alleged cancer links to its heartburn drug Zantac. News that the majority of lawsuits relating to were being settled for $2.2bn materially de-risks the investment case. Looking ahead, strong execution of the growth strategy and clinical pipeline is likely to be the key focus for shareholders moving forward. So far so good, but remember, the drug approval process is long and expensive, with many treatments never seeing the light of day." HL forecast the forward PE of 8.6 with a forecast dividend yield of 4.4% |
Posted at 11/10/2024 07:25 by geckotheglorious On a positive sideHargreaves: Buy GSK before Zantac discount goes GSK (GSK) is drawing a line under its Zantac litigation with a bumper payout which ‘substantially derisks’ the investment case, says Hargreaves Lansdown. Shares in the Citywire Elite Companies AAA-rated pharmaceutical giant climbed 3.2% to £15.05 yesterday after it confirmed it had paid $2.2bn to settle 80,000 cases in US courts over claims that a version of its heartburn treatment Zantac caused cancer. The payment covers 93% of claims but GSK accepts no wrongdoing. It will also pay $70m in a separate but related action. Analyst Derren Nathan said the outcome was ‘significantly better’ than expected, with some estimates as high as $45bn. ‘Looking ahead, GSK’s operational performance should be the key driver of investment,’ he said. ‘Execution has been impressive of late, with two upgrades already in the bag this year.’ It has faced headwinds in key vaccine programmes but overall, ‘recent clinical progress elsewhere in the portfolio has also seen a bigger share of successes than failures’. ‘The upcoming Zantac settlements substantially derisk the investment case for GSK shares which are trading at a hefty discount to the sector, meaning this could be an opportune time to consider increasing exposure to the stock,’ he said. |
Posted at 10/10/2024 15:41 by geckotheglorious GSK update eases investors’ fears as focus turns to vaccinesFTSE 100 pharmaceutical giant resolves legal case over Zantac drug as concern shifts to uptake of firm's key vaccines. Relief for GSK investors after the drugs giant moved to end two years of Zantac litigation uncertainty was today balanced by near-term worries over the uptake of key vaccines. GSK shares reached early afternoon 5% or 70p higher at 1528p, below the initial 10% uptick predicted by Jefferies analysts following last night’s disclosure. Jefferies said the settlement of 93% of Zantac liability cases for $2.2 billion is equivalent to about 40p a share and compared with its own $2 billion-$3.5 billion estimate. GSK, which admitted no liability, intends to fund the costs from existing financial resources and said there will be no impact on its “growth agenda or investment plans”. Its dividend policy for a payout equivalent to 40%-60% of earnings is unchanged, it told City analysts. Having noted higher previous product liability settlements in the pharma industry, UBS said the value of the GSK agreement should be a positive surprise to investors. It said: “We see the settlement as a clear positive, removing a major overhang and uncertainty for investors.” The bank pointed out that the remaining 7% of cases were outstanding because the company had chosen to approach the 10 largest plaintiff firms as a priority. The process is set to conclude by the end of the first half of 2025. Like counterparts at Jefferies, UBS warned that other factors may continue to hang over GSK’s valuation despite the removal of Zantac uncertainty. UBS said these near-term challenges included weak uptake for the respiratory syncytial virus (RSV) product Arexvy and increasing competition in long-acting HIV prevention. It also flagged slower-than-expected uptake of shingles vaccine Shingrix in China. Launched in the third quarter of 2023 and available in major retail pharmacies, Arexvy generated £244 million in sales in the first six months of the year. It had two-thirds of the retail vaccination share in the second quarter, but demand decreased overall in line with anticipated respiratory virus seasonality patterns. UBS has a Neutral stance and price target of 1,580p, while Jefferies had a price target of 2,000p prior to yesterday’s legal developments. The US bank said: “Concerns linger over sales expectations for RSV vaccine Arexvy in both the second half and 2025 given recent slow US RSV vaccine uptake and data supporting an every three year re-vaccination schedule. “In addition, investors continue to debate the sustainability of the Shingrix franchise, given US sales declines and potential concerns around uptake in China.” GSK is due to post third-quarter results on 30 October, having upgraded full-year guidance in July as new launches in oncology boosted sales growth in its Specialty Medicines division. Turnover is now expected to grow by between 7% and 9% and core earnings per share in the range of 10% and 12%. It recently paid a 15p a share quarterly dividend as part of plans to distribute 60p a share across the year. Shore Capital points out that shares trade on a forward looking multiple of 8.1 times, a significant discount to peers and below the 12 times that GSK has historically commanded. It believes shares deserve to be at 2,200p. Analyst Sean Conroy expects that the Zantac developments will serve as a clearing event for GSK and be broadly well received. He added: “This now provides an excellent opportunity for the shares to properly re-rate and allow people to refocus their attention on the improving growth outlook GSK has been delivering since the demerger of Haleon" |
Posted at 12/9/2024 06:16 by the grumpy old men Issued: 12 September 2024, London UKGSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme · A vaccine candidate formulation demonstrated positive A and B strain immune responses relative to standard of care in both younger and older adults · mRNA platform elicits strong overall antibody titres with an acceptable safety profile · Data support progression to phase III clinical trials GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal influenza vaccine programme. The trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza A and B strains, compared to the current standard of care. In both younger and older adults, pre-defined success criteria were met. Interim data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested. These results build on the previous phase II trial and confirm the mRNA platform elicits strong overall antibody titres with an acceptable safety profile. With these results, the GSK mRNA seasonal influenza vaccine programme will progress into late-stage clinical development. GSK's Chief Scientific Officer, Tony Wood said: "This marks a significant advancement in our mRNA programme and these data support moving into late-stage development. Ultimately, our goal is to develop a new best-in-class vaccine to bring greater protection to people through the influenza season." GSK recently signed a new licensing agreement with CureVac to assume full control of developing and manufacturing influenza and COVID-19 candidate vaccines. GSK continues to develop and optimise its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing. About study NCT06431607 The phase II study assesses the reactogenicity, safety, and immunogenicity of different dose levels of a modified, multivalent vaccine candidate, encoding antigens matched to all three WHO-recommended influenza strains. The study includes 250 healthy younger adults aged 18 to 64 and 250 healthy older adults aged 65 to 85. In each age group, different dose levels were tested in comparison to an age-appropriate, licensed comparator vaccine. |
Posted at 12/9/2024 06:15 by the grumpy old men Issued: 11 September 2024, London UKStatement: Zantac (ranitidine) litigation - Dixon case GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Mr. Isaac Dixon, resolving the prostate cancer case filed in Illinois State Court. GSK does not admit any liability in this settlement. The case will now be dismissed. Since 2019, following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
